A REVIEW ON NANOPARTICLES BASED DRUG DELIVERY SYSTEM OF CANCER THERAPY

While targeted drug delivery represents a significant leap forward in oncology, its success is often hampered by the complex nature of tumor heterogeneity and the restrictive conditions of the local microenvironment. Nanotechnology provides a sophisticated solution to these hurdles, offering a platform for the high-precision targeting of malignant cells that spares healthy surrounding tissue. By engineering nanoparticles to bypass physiological barriers and navigate the tumor landscape, researchers can deliver therapeutic payloads directly where they are most needed. Strategic modifications to the nanoparticle surface—such as functionalization for better stability and extended circulation not only improve cellular uptake but also help overcome persistent clinical issues like multidrug resistance and poor penetration into dense, solid tumors. Because these systems can be programmed for controlled, sustained release, they ensure a more consistent therapeutic effect over time. Ultimately, the continued evolution of nanomedicine is paving the way for a paradigm shift toward personalized oncology, where treatments are specifically calibrated to the unique biological profile of each patient.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-04-15
DOI
https://doi.org/10.5281/zenodo.19593737
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A REVIEW ON NANOPARTICLES BASED DRUG DELIVERY SYSTEM OF CANCER THERAPY

Nainsi Kumari, Anshu Kumar, Shubham Singh, Sindhu Raj Sinha et al.
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

A REVIEW ON NANOPARTICLES BASED DRUG DELIVERY SYSTEM OF CANCER THERAPY

Nainsi Kumari, Anshu Kumar, Shubham Singh, Sindhu Raj Sinha, Ritesh Kumar Singh, Saurav Kumar, Rakesh Kumar Sahu*
article en

Abstract

While targeted drug delivery represents a significant leap forward in oncology, its success is often hampered by the complex nature of tumor heterogeneity and the restrictive conditions of the local microenvironment. Nanotechnology provides a sophisticated solution to these hurdles, offering a platform for the high-precision targeting of malignant cells that spares healthy surrounding tissue. By engineering nanoparticles to bypass physiological barriers and navigate the tumor landscape, researchers can deliver therapeutic payloads directly where they are most needed. Strategic modifications to the nanoparticle surface—such as functionalization for better stability and extended circulation not only improve cellular uptake but also help overcome persistent clinical issues like multidrug resistance and poor penetration into dense, solid tumors. Because these systems can be programmed for controlled, sustained release, they ensure a more consistent therapeutic effect over time. Ultimately, the continued evolution of nanomedicine is paving the way for a paradigm shift toward personalized oncology, where treatments are specifically calibrated to the unique biological profile of each patient.

Zenodo (CERN European Organization for Nuclear Research)
Maharashtra Hybrid Seeds (India) (IN)
Openalex Percentile: Top 8%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.